<DOC>
	<DOCNO>NCT01513057</DOCNO>
	<brief_summary>An open-label , balance , randomize , two-treatment , two-period , two sequence , single dose , crossover , bioequivalence study Mycophenolate mofetil 250 mg Capsule Dr. Reddy 's Laboratories limit , compare Cellcept 250 mg Capsule Roche Laboratories healthy , adult , human , male subject feed condition .</brief_summary>
	<brief_title>Bioequivalence Study Mycophenolate Mofetil 250 mg Capsule , Under Fed Conditions</brief_title>
	<detailed_description>This open-label , balance , randomize , two-treatment , two-sequence , two-period , single dose , crossover bioequivalence study healthy , adult , human , male subject feed conditions.64 healthy male adult enrolled.A washout period 07 day maintain successive dose days.One capsule contain mycophenolate mofetil 250 mg administer orally 240 mL water sit posture , overnight fast least 10 hour period . This activity follow mouth check ass compliance dosing . The subject allow lie first two hour dose .</detailed_description>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Healthy , adult , human male volunteer 18 55 year age ( inclusive ) live around Ahmedabad city western part India . Having Body Mass Index ( BMI ) 18.5 24.9 ( inclusive ) , calculate weight kg/height meter2 . Have significant disease clinically significant abnormal finding screen , medical history , physical examination , laboratory evaluation , 12 lead ECG Xray chest recording . Able comply study procedure , opinion Principal investigator . Able give voluntary write informed consent participation study . Known hypersensitivity idiosyncratic reaction Mycophenolate mofetil relate drug . Any disease condition compromise haemopoietic , renal , hepatic , endocrine , pulmonary , central nervous , cardiovascular , immunological , dermatological , gastrointestinal body system . Ingestion medicine time 14 day dose PeriodI . In case subject selection discretion Principal Investigator . Any history presence asthma ( include aspirin induce asthma ) nasal polyp NSAID induce urticaria . A recent history alcoholism ( &lt; 2 year ) moderate ( 180 mL/day ) alcohol use , consumption alcohol within 48 hour prior receive study medicine . Smokers , smoke 10 10 cigarettes/day inability abstain smoking study . Consumption Grapefruits product within period 48 hour prior dose . The presence clinically significant abnormal laboratory value screen . Use recreational drug history drug addiction test positive prestudy drug scan . History psychiatric disorder . A history difficulty donate blood . Donation blood ( 1 unit 350 mL ) receipt investigational product participation drug research study within period 90 day prior first dose study medicine . Elimination halflife study drug take consideration inclusion subject study . Note : If subject participate study blood loss â‰¤ 200 mL , subject could enrol 60 day last sample previous study . A positive hepatitis screen include hepatitis B surface antigen HCV antibody . A positive test result HIV antibody and/or syphilis . An unusual diet , whatever reason ( e.g . lowsodium ) , four week prior receive study medicine throughout subject ' participation study . In case subject selection discretion Principal Investigator . All enrolled subject satisfied inclusion exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>bioequivalence</keyword>
	<keyword>Mycophenolate Mofetil</keyword>
	<keyword>crossover</keyword>
</DOC>